When you step into Jiangxi Dadi Pharmaceutical Co., Ltd., located in the Lianhua Industrial Park, you will be greeted by a spotless comprehensive preparation workshop, where advanced production lines are operating in an orderly fashion. Dadi Pharmaceutical regards technological innovation as the basis for the company's survival. With the idea of "specialization, excellence, and innovation," Dadi Pharmaceutical is continuously improving its market competitiveness and economic efficiency, and has achieved remarkable success in its industry.
Dadi Pharmaceutical was formerly known as the state-owned Lianhua Pharmaceutical Factory, established in 1969. In December 2000, Lianhua County transformed the Lianhua Pharmaceutical Factory through equity transfer and formed Jiangxi Dadi Pharmaceutical Co., Ltd. After more than 20 years of development, Dadi Pharmaceutical has become a high-tech enterprise mainly engaged in the research and development, production, and sales of raw materials, intermediate products, traditional Chinese medicine preparations, plastic additives, and other products.
"Technological innovation and cost control are the keys to occupying a place in the business world. In recent years, the company has invested RMB 200 million in technological transformation and allocated 4% of its annual sales revenue as research and development funds to comprehensively improve production capacity and enhance its core competitiveness," said the Vice General Manager of Dadi Pharmaceutical. Currently, the company's quinolone products, levofloxacin hydrochloride, levofloxacin lactate, ciprofloxacin hydrochloride, and simvastatin raw materials and intermediate products, have a market share of over 30% through continuous optimization of its technology and processes.
In order to steadily expand its market share, the company is planning to develop the end market for its moxifloxacin raw materials based on the latest generation of quinolone products it has developed. Furthermore, in order to promote the company's early success in its IPO and enhance its sustainable operating capacity, the company has been continuously strengthening the development of various dosage forms of traditional Chinese medicine, developing the upstream and downstream industry chains of quinolone drugs, and forming unique advantages in the industrialization of characteristic raw materials.
Dadi Pharmaceutical has established a sound management system in terms of production, quality control, cost control, and other aspects, and has obtained several certifications, including the GMP certification for pharmaceutical products, the ISO 14001 environmental management system certification, and the OHSAS 18001 occupational health and safety management system certification. This further demonstrates its excellence as a leading enterprise in the pharmaceutical industry.
In summary, with its commitment to technological innovation, cost control, and quality management, it is not surprising to see Dadi Pharmaceutical's success in the industry. Dadi Pharmaceutical has proven that an old-fashioned pharmaceutical enterprise can still make a name for itself with excellent products and cutting-edge technology.